Near 500 key enterprises in life health industry have clustered at Hangzhou High-Tech Zone (Binjiang) up to now, including listed enterprises and unicorns like Tigermed, Venus Medtech, and DXY. HHTZ’s revenue from biological medicine and health industry reached 20.42 billion yuan from January to September 2021, up 16.6% compared with the same period last year. HHZT is aiming to develop life health industry into the third 100-million-yuan-level industry following digital security and protection and network communication, making it a scientific and innovation highland for life health with international competitiveness.